Ligand Pharmaceuticals Incorporated (LGND) compared with its closest peers (ARVN, SDGR, RCUS, XERS, RIGL): P/E 41.0 vs industry 17.2. Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Arvinas, Schrödinger, Arcus Biosciences, Xeris Biopharma, Rigel Pharmaceuticals, Keros Therapeutics, Ironwood Pharmaceuticals, Akebia Therapeutics, AnaptysBio and CorMedix share Ligand Pharmaceuticals's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Arvinas, Inc. (ARVN) | $612.67M | 65.9 |
| Schrödinger, Inc. (SDGR) | $1.46B | -12.7 |
| Arcus Biosciences, Inc. (RCUS) | $3.82B | -7.2 |
| Xeris Biopharma Holdings, Inc. (XERS) | $1.50B | — |
| Rigel Pharmaceuticals, Inc. (RIGL) | $857.22M | 13.7 |
| Keros Therapeutics, Inc. (KROS) | $219.29M | 8.8 |
| Ironwood Pharmaceuticals, Inc. (IRWD) | $708.05M | 4.1 |
| Akebia Therapeutics, Inc. (AKBA) | $243.63M | -80.3 |
| AnaptysBio, Inc. (ANAB) | $1.68B | -105.4 |
| CorMedix Inc. (CRMD) | $638.36M | 3.4 |
| Stock P/E | 41.0 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | 88.6% |
| vs Industry | 138.7% |
LGND overview · LGND earnings · LGND financials · LGND KPIs · LGND documents · LGND ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.